Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Oct 18 - Oct 23
However, NICE guideline NG28 specifies continuation criteria: treatment should be reviewed after approximately 6 months and only continued if you've achieved both a reduction in HbA1c of at least 11 mmol/mol (1%) and weight loss of at least 3%
It is not an FDA-approved drug or medical device
3 Multiple clinical trials have shown GLP-1RAs reduce cardiovascular risks in patients with diabetes and atherosclerotic cardiovascular disease (ASCVD), or high cardiovascular risk independent of HbA1C
Dosing tiers: Fasted administration is standard protocol
You start with a dosage of 0.6 mg
US$ 23.52
US$ 24.94
US$ 24.26
US$ 27.95
